PE20141539A1 - Una nueva composicion terapeutica que contiene apomorfina como principio activo - Google Patents
Una nueva composicion terapeutica que contiene apomorfina como principio activoInfo
- Publication number
- PE20141539A1 PE20141539A1 PE2014000051A PE2014000051A PE20141539A1 PE 20141539 A1 PE20141539 A1 PE 20141539A1 PE 2014000051 A PE2014000051 A PE 2014000051A PE 2014000051 A PE2014000051 A PE 2014000051A PE 20141539 A1 PE20141539 A1 PE 20141539A1
- Authority
- PE
- Peru
- Prior art keywords
- composition containing
- therapeutic composition
- active principle
- new therapeutic
- containing apomorphine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE SOLUCION QUE COMPRENDE: i) 10 A 70 mg/ml DE APOMORFINA COMO SUSTANCIA ACTIVA; ii) 0,1 A 80%/ml DE UN CODISOLVENTE MISCIBLE EN AGUA TAL COMO UN ALCOHOL, POLIOL, POLIETER O UNA MEZCLA DE LOS MISMOS; iii) UN ANTIOXIDANTE TAL COMO ACIDOS Y SUS SALES, VITAMINAS, AMINOACIDOS, SULFITOS, ENTRE OTROS; Y iv) AGUA; OPCIONALMENTE PRESENTA UN TENSIOACTIVO, EL pH DE LA COMPOSICION ES SUPERIOR A 4. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11290320A EP2545905A1 (en) | 2011-07-11 | 2011-07-11 | A new therapeutical composition containing apomorphine as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141539A1 true PE20141539A1 (es) | 2014-10-25 |
Family
ID=46514305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000051A PE20141539A1 (es) | 2011-07-11 | 2012-07-11 | Una nueva composicion terapeutica que contiene apomorfina como principio activo |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US11026938B2 (es) |
| EP (2) | EP2545905A1 (es) |
| JP (2) | JP6356064B2 (es) |
| KR (1) | KR101990897B1 (es) |
| CN (2) | CN108434094A (es) |
| AU (1) | AU2012283381B2 (es) |
| BR (1) | BR112014000306B1 (es) |
| CA (1) | CA2841807C (es) |
| CL (1) | CL2014000050A1 (es) |
| CO (1) | CO6870038A2 (es) |
| CR (1) | CR20140005A (es) |
| CU (1) | CU24159B1 (es) |
| DO (1) | DOP2014000003A (es) |
| EA (1) | EA025870B1 (es) |
| EC (1) | ECSP14013200A (es) |
| GE (1) | GEP20196969B (es) |
| GT (1) | GT201400003A (es) |
| IL (1) | IL230308A (es) |
| IN (1) | IN2014DN00090A (es) |
| MA (1) | MA35411B1 (es) |
| MX (2) | MX2014000454A (es) |
| MY (1) | MY168212A (es) |
| NI (1) | NI201400003A (es) |
| PE (1) | PE20141539A1 (es) |
| SG (1) | SG10201605491PA (es) |
| TN (1) | TN2014000001A1 (es) |
| UA (1) | UA113962C2 (es) |
| WO (1) | WO2013007381A1 (es) |
| ZA (1) | ZA201309711B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545905A1 (en) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
| US9999674B2 (en) * | 2012-06-05 | 2018-06-19 | Neuroderm, Ltd. | Compositions comprising apomorphine and organic acids and uses thereof |
| EP2918266A1 (en) | 2014-03-11 | 2015-09-16 | CDRD Berolina AB | Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease |
| EP2979688A1 (en) * | 2014-08-01 | 2016-02-03 | Britannia Pharmaceuticals Limited | Composition containing Apomorphine and a Divalent Metal Cation |
| WO2016103262A2 (en) * | 2014-12-23 | 2016-06-30 | Neuroderm Ltd | Crystal forms of apomorphine and uses thereof |
| US20180280465A1 (en) * | 2015-09-28 | 2018-10-04 | Ever Neuro Pharma Gmbh | Aqueous composition of apomorphine for subcutaneous administration |
| WO2020243538A1 (en) * | 2019-05-31 | 2020-12-03 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
| US20220313682A1 (en) * | 2019-08-07 | 2022-10-06 | Aclipse One Inc. | Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol |
| US20230181570A1 (en) | 2020-05-20 | 2023-06-15 | Medrx Co., Ltd. | Transdermal Formulation Containing Apomorphine |
| WO2022271537A1 (en) * | 2021-06-25 | 2022-12-29 | President And Fellows Of Harvard College | Compositions and methods relating to injectable microemulsions |
| WO2023242355A1 (en) | 2022-06-15 | 2023-12-21 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1662566A1 (ru) * | 1988-03-05 | 1991-07-15 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Способ стабилизации инъекционного раствора апоморфина |
| JP2822049B2 (ja) * | 1989-02-02 | 1998-11-05 | ゼリア新薬工業株式会社 | 水性製剤組成物 |
| ATE290864T1 (de) * | 1993-03-26 | 2005-04-15 | Franciscus Wilhelmus He Merkus | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin |
| US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| US5945117A (en) | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| JP3723857B2 (ja) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
| US6011043A (en) | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
| US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
| US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
| BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
| US20030008878A1 (en) | 2001-03-09 | 2003-01-09 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| US20020169166A1 (en) | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| ITMI20011321A1 (it) * | 2001-06-22 | 2002-12-22 | Chiesi Farma Spa | Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| US6939094B2 (en) | 2003-01-28 | 2005-09-06 | Macro Technologies Inc. | Autonomous power interface for modifying limited rotation speed of a machine |
| JP2007524605A (ja) | 2003-04-03 | 2007-08-30 | ピーディーエル バイオファーマ，インコーポレイティド | インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用 |
| US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
| EP1714648A4 (en) * | 2004-02-09 | 2010-05-26 | Aska Pharm Co Ltd | COMBINATION DRUGS |
| KR20090027218A (ko) | 2006-05-24 | 2009-03-16 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 면역원성이 감소된, 고친화도 인간 및 인간화된 항-α5β1 인테그린 작용 블로킹 항체 |
| US20080171072A1 (en) * | 2006-08-11 | 2008-07-17 | Frank Burczynski | Ocular inserts containing apomorphine |
| US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| EP2057982A1 (en) * | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
| CN101712675B (zh) * | 2008-10-07 | 2013-07-03 | 江苏恒谊药业有限公司 | 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用 |
| EP2545905A1 (en) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | A new therapeutical composition containing apomorphine as active ingredient |
-
2011
- 2011-07-11 EP EP11290320A patent/EP2545905A1/en not_active Withdrawn
-
2012
- 2012-07-11 MY MYPI2014000016A patent/MY168212A/en unknown
- 2012-07-11 CA CA2841807A patent/CA2841807C/en active Active
- 2012-07-11 UA UAA201400117A patent/UA113962C2/uk unknown
- 2012-07-11 BR BR112014000306-8A patent/BR112014000306B1/pt active IP Right Grant
- 2012-07-11 IN IN90DEN2014 patent/IN2014DN00090A/en unknown
- 2012-07-11 KR KR1020147001302A patent/KR101990897B1/ko active IP Right Grant
- 2012-07-11 AU AU2012283381A patent/AU2012283381B2/en active Active
- 2012-07-11 JP JP2014519451A patent/JP6356064B2/ja active Active
- 2012-07-11 EA EA201400067A patent/EA025870B1/ru not_active IP Right Cessation
- 2012-07-11 WO PCT/EP2012/002916 patent/WO2013007381A1/en active Application Filing
- 2012-07-11 SG SG10201605491PA patent/SG10201605491PA/en unknown
- 2012-07-11 CN CN201810378574.0A patent/CN108434094A/zh active Pending
- 2012-07-11 MX MX2014000454A patent/MX2014000454A/es unknown
- 2012-07-11 CU CU20140005A patent/CU24159B1/es active IP Right Grant
- 2012-07-11 CN CN201280034745.9A patent/CN103826612B/zh active Active
- 2012-07-11 PE PE2014000051A patent/PE20141539A1/es active IP Right Grant
- 2012-07-11 EP EP12735463.7A patent/EP2731589A1/en active Pending
- 2012-07-11 GE GEAP201213377A patent/GEP20196969B/en unknown
-
2013
- 2013-12-20 ZA ZA2013/09711A patent/ZA201309711B/en unknown
-
2014
- 2014-01-02 TN TNP2014000001A patent/TN2014000001A1/en unknown
- 2014-01-02 IL IL230308A patent/IL230308A/en active IP Right Grant
- 2014-01-07 CR CR20140005A patent/CR20140005A/es unknown
- 2014-01-09 CL CL2014000050A patent/CL2014000050A1/es unknown
- 2014-01-09 DO DO2014000003A patent/DOP2014000003A/es unknown
- 2014-01-09 GT GT201400003A patent/GT201400003A/es unknown
- 2014-01-09 NI NI201400003A patent/NI201400003A/es unknown
- 2014-01-10 US US14/152,000 patent/US11026938B2/en active Active
- 2014-01-10 MX MX2021010046A patent/MX2021010046A/es unknown
- 2014-02-03 MA MA36727A patent/MA35411B1/fr unknown
- 2014-02-04 CO CO14022989A patent/CO6870038A2/es unknown
- 2014-02-11 EC EC2014013200A patent/ECSP14013200A/es unknown
-
2016
- 2016-06-30 US US15/199,070 patent/US20160310480A1/en not_active Abandoned
- 2016-12-08 JP JP2016238705A patent/JP2017081947A/ja active Pending
-
2017
- 2017-12-13 US US15/840,585 patent/US20180098981A1/en not_active Abandoned
-
2021
- 2021-04-30 US US17/245,209 patent/US11766431B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
| CL2013003163A1 (es) | Composición transdermica de ibuprofeno, util en el tratamiento del dolor o la inflamacion. | |
| PE20160874A1 (es) | Compuestos quimicos | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
| AR084285A1 (es) | Composiciones inmunogenicas | |
| PE20160681A1 (es) | Formulacion de premezcla de dexmedetomidina | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| PE20130589A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| PE20090910A1 (es) | Composicion topica | |
| UY32691A (es) | Compuestos de 1h-imidazo-[4,5-c]-quinolinona | |
| AR086824A1 (es) | Composicion oftalmica que comprende un mediador lipido antiinflamatorio esterificado y metodo de tratamiento | |
| AR076864A1 (es) | Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos | |
| PE20120788A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos | |
| BR112017013471A2 (pt) | Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit. | |
| CO7170176A2 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa11b-hidroxiesteroide tipo 1(11b-hsd1) o sal farmaceúticamente aceptable del mismo, método para producir el mismo, y composición farmaceútica que contiene el mismo como ingrediente activo | |
| CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
| TN2014000031A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| PA8771101A1 (es) | Sales de adicion de acido, hidratos y polimorfos de la etil-amida del acido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxilico, y formulaciones que comprenden estas formas | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| BR112014004732A2 (pt) | composto benzotiazolona | |
| PE20130374A1 (es) | Composicion farmaceutica que comprende ibuprofeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |